Analysts Set ADC Therapeutics SA (NYSE:ADCT) Target Price at $5.00

Shares of ADC Therapeutics SA (NYSE:ADCT) have received an average rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $5.00.

ADCT has been the subject of several research reports. HC Wainwright lowered shares of ADC Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, June 8th. Wall Street Zen upgraded shares of ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Stephens reissued an “overweight” rating and set a $5.00 target price on shares of ADC Therapeutics in a research note on Thursday, June 4th. Weiss Ratings restated a “sell (d-)” rating on shares of ADC Therapeutics in a report on Friday, July 17th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ADC Therapeutics in a research report on Thursday, June 4th.

Hedge Funds Weigh In On ADC Therapeutics

Hedge funds have recently modified their holdings of the stock. Eventide Asset Management LLC purchased a new position in ADC Therapeutics in the 4th quarter worth about $11,875,000. AXQ Capital LP purchased a new stake in ADC Therapeutics during the fourth quarter valued at about $57,000. ProShare Advisors LLC boosted its holdings in shares of ADC Therapeutics by 27.0% in the fourth quarter. ProShare Advisors LLC now owns 15,727 shares of the company’s stock worth $56,000 after buying an additional 3,339 shares during the period. Kingswood Wealth Advisors LLC acquired a new position in shares of ADC Therapeutics in the fourth quarter worth about $371,000. Finally, Revolve Wealth Partners LLC acquired a new position in shares of ADC Therapeutics in the second quarter worth about $107,000. 41.10% of the stock is currently owned by institutional investors and hedge funds.

ADC Therapeutics Stock Down 3.1%

Shares of ADC Therapeutics stock opened at $0.97 on Tuesday. The firm has a market cap of $123.33 million, a price-to-earnings ratio of -1.46 and a beta of 1.89. The business has a fifty day simple moving average of $1.14 and a 200-day simple moving average of $2.76. ADC Therapeutics has a fifty-two week low of $0.78 and a fifty-two week high of $4.98.

ADC Therapeutics (NYSE:ADCT) last announced its earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.11. The firm had revenue of $19.25 million for the quarter, compared to the consensus estimate of $18.89 million. Analysts anticipate that ADC Therapeutics will post -0.8 earnings per share for the current fiscal year.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.